Thalamic atrophy is associated with development of clinically definite multiple sclerosis. - Test2 - elhamkhani - TriplyDB

Thalamic atrophy is associated with development of clinically definite multiple sclerosis.

Thalamic atrophy is associated with development of clinically definite multiple sclerosis.

http://www.wikidata.org/entity/Q30619701

about

Optimizing treatment success in multiple sclerosis Advanced and Conventional Magnetic Resonance Imaging in Neuropsychiatric Lupus Clinical relevance of brain volume measures in multiple sclerosis.MRI evaluation of grey matter atrophy and disease course in multiple sclerosis: an overview of current knowledge.Thalamus pathology in multiple sclerosis: from biology to clinical application.Subcortical brain segmentation of two dimensional T1-weighted data sets with FMRIB's Integrated Registration and Segmentation Tool (FIRST).Brain atrophy in multiple sclerosis: therapeutic, cognitive and clinical impact.Brain MRI atrophy quantification in MS: From methods to clinical application.MRI correlates of disability progression in patients with CIS over 48 months.Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine.Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients.Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod Humoral response to EBV is associated with cortical atrophy and lesion burden in patients with MS.Gray Matter Involvement in Radiologically Isolated Syndrome.The prognostic utility of MRI in clinically isolated syndrome: a literature review.Effect of teriflunomide on cortex-basal ganglia-thalamus (CxBGTh) circuit glutamatergic dysregulation in the Theiler's Murine Encephalomyelitis Virus mouse model of multiple sclerosis.Radiologically isolated syndrome: An update on a rare entity.The yearly rate of Relative Thalamic Atrophy (yrRTA): a simple 2D/3D method for estimating deep gray matter atrophy in Multiple Sclerosis Cognitive deficits in pediatric-onset multiple sclerosis: what does the future hold?Subcortical deep gray matter pathology in patients with multiple sclerosis is associated with white matter lesion burden and atrophy but not with cortical atrophy: a diffusion tensor MRI study.Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis.Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study.Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol: Results from MS-MRIUS, a Longitudinal Observational, Multicenter Real-World Outcome Study in Patients with Relapsing-Remitting MS.Pathological cut-offs of global and regional brain volume loss in multiple sclerosis.Mapping of thalamic magnetic susceptibility in multiple sclerosis indicates decreasing iron with disease duration: A proposed mechanistic relationship between inflammation and oligodendrocyte vitality.The impact of vascular risk factors on brain volume and lesion load in patients with early multiple sclerosis.Longitudinal Mixed-Effect Model Analysis of the Association between Global and Tissue-Specific Brain Atrophy and Lesion Accumulation in Patients with Clinically Isolated Syndrome.Thalamus Degeneration and Inflammation in Two Distinct Multiple Sclerosis Animal Models.The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical Trials.Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β-1a.Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis.Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.Brain atrophy measurements should be used to guide therapy monitoring in MS - YES.Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome.Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients.Localized atrophy of the thalamus and slowed cognitive processing speed in MS patients.Spin echo transverse relaxation and atrophy in multiple sclerosis deep gray matter: A two-year longitudinal study.Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations.Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis.

P2860

Q26771968-2786DE9F-917E-4538-96C2-BE05FF343A27 Q26799922-B0F7AB0E-31F7-4087-A078-41901DB67FD9 Q30738659-C48AB36D-2441-4FD9-BB4D-FE7F0C19DB05 Q30769070-4BFB6BB0-B378-4798-A0EE-FB2A19C41BB7 Q30871067-58525AFF-E2D5-49D9-94A2-86E463538849 Q30885558-D498406F-969F-4C79-BC3F-C51D6DE708BA Q31070072-A2E43CD2-72B6-439C-806D-F35CFA0D10C9 Q31149648-62AF393A-B405-44E0-9906-075DAE714DD7 Q34431806-C22EB949-27C5-46D5-A94F-988C40D4CF0A Q35997017-9CB5E27E-6EAF-4A8E-A4EC-E26F42CA4AD6 Q36093231-B171B5FC-1276-4D10-A691-2BC42B37552F Q36097847-610B982B-FE63-4539-A332-25DBF75CBE6D Q36451667-D8B6B7F1-F037-4F7B-97B5-211E66D90230 Q37205897-CF9D09D4-05E3-4FA1-BDCC-8BFDD261DD1B Q38211996-2F3A756F-801C-4619-A7EF-796967253BB4 Q38630407-CDCE1903-53D3-4379-9E70-0FDA207D601A Q38861838-C09F8C91-E2FD-405D-828A-CD87B4B83CA2 Q39131745-FAC18C6A-5522-4591-A77F-9C2899E32FCB Q39191862-A6C3E88A-B405-4859-B77C-102695C25EE1 Q44486220-7FFCA28A-45B9-4C6F-A1EF-8B70EE61BD18 Q47242221-C723F29E-3C55-4B69-A02A-EA892FB6248A Q47438663-F97CF159-60DB-4003-A12A-76F68E4A1E28 Q47820950-0F0904C5-BCFA-43D0-A932-48C42044CD71 Q47967210-17B8F4F5-922E-43D4-A77D-7CA056ED293F Q47989756-7AEE6409-13D4-46B7-8919-167EA9E8DFC6 Q48020921-7BD7D405-AE37-4931-9F73-031EFFFA1765 Q48108313-ADF35FC9-ADF8-4602-B68C-499299DBCDFD Q48127262-0665C24D-AE81-4541-A253-AF0B188AB544 Q48168382-855BD056-D81E-4CBE-861D-76E83AA01B93 Q48215414-8FAB6A4D-8B4C-42C1-9E59-203765811DC3 Q48306943-EA0212CB-72F1-47C4-821C-9940702FDA35 Q48581094-15D7163E-08A0-467E-9CF3-50567B6806D4 Q48660868-6FE33852-4661-4B2F-95F1-F468619242D1 Q48704199-B31875F4-5C44-4F11-A266-47C052380603 Q48711608-02D008AC-38C3-4E84-BF74-A005DAF5038B Q48901292-3782D5F3-377B-4025-A82B-FCB670BE4B7E Q50550817-5B90FAF0-A0D9-4664-B1E9-99205F9C7CEE Q51672185-5715C808-65CC-46A0-BD4B-2BF6EA8B0208 Q52097333-98C80F76-2C20-49D0-98E2-915A5C7B74E6 Q52141693-D9FF7A86-A506-4CFA-86FF-7A38A70D050E

P2860

Thalamic atrophy is associated with development of clinically definite multiple sclerosis.

http://www.wikidata.org/entity/Q30619701

description

2013 nî lūn-bûn

@nan

2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Thalamic atrophy is associated ...... y definite multiple sclerosis.

@ast

Thalamic atrophy is associated ...... y definite multiple sclerosis.

@en

type

label

Thalamic atrophy is associated ...... y definite multiple sclerosis.

@ast

Thalamic atrophy is associated ...... y definite multiple sclerosis.

@en

prefLabel

Thalamic atrophy is associated ...... y definite multiple sclerosis.

@ast

Thalamic atrophy is associated ...... y definite multiple sclerosis.

@en

P1433

Q30619701-4FD955D8-C287-4083-9A9F-262F40E10085

P1476

Q30619701-CD071F95-3447-413E-BC6F-B7F3043CA6EC

P2093

Q30619701-044F67E8-9922-400D-9A15-5680E3EDB02F

Q30619701-3D111E46-054F-45FE-A8E9-9E66B89315AA

Q30619701-592B9638-CC98-4002-85C6-9C2BF88BD954

Q30619701-75334661-D18F-40E6-8403-D8B956E780C1

Q30619701-7590467B-531E-40A5-8030-80F5B757C78C

Q30619701-8485C2EC-4E31-4484-A411-AF650AA7AF75

Q30619701-955275F6-FBE1-46A0-A52B-E964AF7923D9

Q30619701-B405CC4F-4484-4D97-B549-5D8A2267167A

Q30619701-BBEF9292-86BA-4A0D-970B-0FCC933C57EA

Q30619701-C60E68C9-3CBA-4419-AED1-9E8E0526357B

P304

Q30619701-CE40BE0B-3E7F-4B6F-AD89-6D7D3B3C86DD

P31

Q30619701-C8390A3C-BAC6-4302-A8B5-FD5143F131A3

P356

Q30619701-05F1EDF1-14C7-457F-B6CE-20A254808E3F

P407

Q30619701-3AD4AB8F-FC6C-4CC2-BAD6-9D2BE880819B

P433

Q30619701-B2DF2FA1-D2A4-49D3-BEA4-FF90A6F0269C

P478

Q30619701-C5BDA18C-FD5D-4533-AF0D-B34854E0326E

P50

Q30619701-36588B81-EDCE-4272-8DDC-DF3A0B0ADF1B

P577

Q30619701-5C07E624-A177-4171-97AF-E82C2C16219C

P698

Q30619701-668C890C-D437-4792-AA6F-3F6A0FE0D252

P921

Q30619701-71C81849-42BE-4BC8-9C9D-9CE63E232C5F

P356

RADIOL.13122424

P1433

P1476

Thalamic atrophy is associated ...... y definite multiple sclerosis.

@en

P2093

Dana Horáková

http://www.w3.org/2001/XMLSchema#string

Ellen Carl

http://www.w3.org/2001/XMLSchema#string

Eva Havrdová

http://www.w3.org/2001/XMLSchema#string

Jan Krasensky

http://www.w3.org/2001/XMLSchema#string

Jesper Hagemeier

http://www.w3.org/2001/XMLSchema#string

Manuela Vaneckova

http://www.w3.org/2001/XMLSchema#string

Michael G Dwyer

http://www.w3.org/2001/XMLSchema#string

Michaela Tyblova

http://www.w3.org/2001/XMLSchema#string

Niels Bergsland

http://www.w3.org/2001/XMLSchema#string

Tomas Kalincik

http://www.w3.org/2001/XMLSchema#string

P304

831-841

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1148/RADIOL.13122424

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

268

http://www.w3.org/2001/XMLSchema#string

P50

Robert Zivadinov

P577

2013-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23613615

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis